Kromek Group plc (AIM:KMK)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 35.65M -20.0% |
| Revenue (ttm) | 27.12M +2.3% |
| Net Income | 733.00K -80.5% |
| EPS | 0.00 -82.9% |
| Shares Out | 655.30M |
| PE Ratio | 54.40 |
| Forward PE | 23.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 904,087 |
| Open | 5.41 |
| Previous Close | 5.40 |
| Day's Range | 5.33 - 5.60 |
| 52-Week Range | 5.20 - 13.00 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+313.6%) |
| Est. Earnings | Jan 19, 2027 |
About Kromek Group
Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets. It offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator t... [Read more]
Financial Performance
In fiscal year 2026, Kromek Group's revenue was 27.12 million, an increase of 2.30% compared to the previous year's 26.51 million. Earnings were 733,000, a decrease of -80.47%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for KMK stock is "Strong Buy." The 12-month stock price target is 23p, which is an increase of 313.60% from the latest price.
News
Kromek Group Earnings Call Transcript: H2 2026
FY 2027 revenue is guided at GBP 30.3 million, with a midterm target of GBP 60 million and 30% EBITDA margin by 2030/2031. Growth is driven by both Advanced Imaging and CBRN, with capacity expansion funded by customers and sufficient working capital facilities in place.
Kromek Group Annual report: H2 2026
Kromek Group has published its H2 2026 annual report on September 21, 2026.
Kromek Group Earnings Call Transcript: H2 2026
Revenue reached GBP 27.1 million with 36% underlying growth, driven by advanced imaging and CBRN detection. Profit before tax was GBP 2.5 million, and the business is well-positioned for continued expansion, with new commercial opportunities in biosecurity and a robust pipeline.
Kromek Group Annual report: H2 2026
Kromek Group has published its H2 2026 annual report on September 18, 2026.
Kromek is moving beyond its Siemens sugar high
Kromek has spent the past year proving that it can grow without relying quite so heavily on a lucrative licensing deal.
Kromek Group Share Price at 8p: Can September Results Deliver?
The Kromek Group share price has drifted back to 8.00p as of 26 August 2026, according to Kalkine, a 5.88% decline from the 8.5p level at which shares in the AIM-listed radiation and bio-detection spe...
Kromek Group Earnings release: H2 2026
Kromek Group released its H2 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kromek Group Earnings Call Transcript: H1 2026
Strong growth in the CZT detector market is driving profitability, with major contracts and a shift to a licensing-heavy model. The company targets £60 million revenue and 30% EBITDA margin in the medium term, supported by robust demand in medical imaging and CBRN, while maintaining independence and disciplined capital allocation.
Kromek Group Quarterly report: H1 2026
Kromek Group has published its H1 2026 quarterly earnings report on January 26, 2026.